For use in individuals with symptoms of cystic fibrosis (CF) or a CFTR-related disorder. This test is NOT indicated for routine carrier screening; refer to Cystic Fibrosis (CFTR) Expanded Variant Panel (2013661).
Massively Parallel Sequencing/Sequencing
New York DOH Approval Status
Lavender or pink (EDTA) or yellow (ACD solution A or B).
New York State Clients: Lavender or pink (EDTA).
Transport 3 mL whole blood. (Min: 2 mL)
Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
Gene Tested: CFTR
|Component Test Code*||Component Chart Name||LOINC|
- CFTR-related disorder